Lung cancer
The immunotherapy treatments listed below are effective at treating lung cancer.
Specific antibodies:
The Ramucircumcab
Ramucirumab is a monoclonal antibody that inhibits the growth of blood vessel malignancies by targeting the VEGFR2/VEGF pathway. Ramucirumab is the first-line treatment for non-small cell lung cancer (NSCLC) patients.
The drug Necitumumab
Necitumumab is a monoclonal antibody that targets the EGFR pathway as a first-line therapy for patients with advanced non-small cell lung cancer (NSCLC).
The drug Bevacizumab
Bevacizumab is an antibody monoclonal that targets the VEGFR/VEGF pathway. Bevacizumab inhibits tumor growth in blood vessels, and the FDA has approved the use of this monoclonal antibody as initial therapy for patients with severe non-small cell lung cancer (NSCLC).
